https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/aibio.spaceen2026-10-30Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/aibio.spaceen2026-10-30Repligen announces $1.0 billion private convertible notes transaction https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/aibio.spaceen2026-10-29PTC reports third-quarter 2026 revenue of $358 million and raises product guidance https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/aibio.spaceen2026-10-29Processa clears VT-7208 CSU IND and names a new executive chair https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/aibio.spaceen2026-10-29Kiora in-licenses late-stage KIO-401 for retinal artery occlusion https://aibio.space/news/azitra-expands-atr-04-trial-rash-kras-mek-inhibitors/aibio.spaceen2026-10-29Azitra expands ATR-04 trial to rash from KRAS and MEK inhibitors https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/aibio.spaceen2026-10-29FOXO to buy Ludwig Enterprises preferred stock with majority voting power https://aibio.space/news/dermata-enrolls-first-participant-tome-clearing-treatment-trial/aibio.spaceen2026-10-29Dermata enrolls first participant in Tome Clearing Treatment trial https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/aibio.spaceen2026-10-29Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena https://aibio.space/news/viking-ligand-dispute-vk2809-license-termination-san-diego-court/aibio.spaceen2026-10-29Viking and Ligand dispute VK2809 license termination in San Diego court https://aibio.space/news/vikings-itc-trade-secret-ruling-against-ascletis-appeal-federal/aibio.spaceen2026-10-29Viking's ITC trade secret ruling against Ascletis is on appeal at Federal Circuit https://aibio.space/news/court-rules-teva-apotex-vandas-hetlioz-patent-suits/aibio.spaceen2026-10-29Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits https://aibio.space/news/indivior-discloses-suboxone-dental-injury-mdl-about-22-098-plaintiffs/aibio.spaceen2026-10-29Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028 https://aibio.space/news/altimmune-draws-10-0-million-third-tranche-hercules-loan-facility/aibio.spaceen2026-10-29Altimmune draws $10.0 million third tranche from Hercules loan facility https://aibio.space/news/european-patent-court-rules-enanta-patent-invalid-paxlovid-suit/aibio.spaceen2026-10-29European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/aibio.spaceen2026-10-29INmune Bio raises $4.50 million in registered direct offering with warrants https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/aibio.spaceen2026-10-29Lexeo Therapeutics files $300 million shelf registration https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/aibio.spaceen2026-10-29Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/aibio.spaceen2026-10-29Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/aibio.spaceen2026-10-29ProKidney files $650 million shelf with $200 million Jefferies sales program https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/aibio.spaceen2026-10-29Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/aibio.spaceen2026-10-29Reviva asks stockholders to approve reverse split of up to 1-for-100